Evidence map›Paper›PMID 31665014›Full record

ArticleVirology journal2019

Monoclonal antibody-based capture ELISA in the diagnosis of previous dengue infection.

Chukiat Sirivichayakul, Kriengsak Limkittikul, Pornthep Chanthavanich, Sutee Yoksan, Anuttarasakdi Ratchatatat, Jacqueline Kyungah Lim, Watcharee Arunsodsai, Arunee Sabchareon

Open access · goldAbstract readEvaluation Study
In one paragraph

Article in Virology journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Integrated One Health strategies in Dengue.One health (Amsterdam, Netherlands) · 2024
    Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Chukiat SirivichayakulDepartment of Tropical Pediatrics, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand. chukiat.sir@mahidol.ac.th.ORCID 0000-0002-6889-2960
Kriengsak LimkittikulDepartment of Tropical Pediatrics, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Pornthep ChanthavanichDepartment of Tropical Pediatrics, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Sutee YoksanCenter for Vaccine Development, Mahidol University, Nakhonpathom, Thailand.
Anuttarasakdi RatchatatatDepartment of Disease Control, Ministry of Public Health, Nonthaburi, Thailand.
Jacqueline Kyungah LimGlobal Dengue and Aedes-Transmitted Diseases Consortium (formerly Pediatric Dengue Vaccine Initiative), International Vaccine Institute, Seoul, South Korea.
Watcharee ArunsodsaiDepartment of Tropical Pediatrics, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Arunee SabchareonDepartment of Tropical Pediatrics, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Mahidol University · THInternational Vaccine Institute · KRMinistry of Public Health · TH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDengue is an important mosquito-borne disease. There is currently only one licensed vaccine for dengue prevention. The vaccine provides higher efficacy in pre-vaccination dengue-seropositive persons but a higher risk of subsequent more severe dengue in dengue-seronegative persons. It is recommended that the dengue vaccine may be given in dengue-seropositive individuals or as mass vaccination without individual pre-vaccination screening in areas where the dengue seroprevalence is > 80% in children aged 9 years. We evaluated a dengue specific immunoglobulin G monoclonal antibody-based capture enzyme-linked immunosorbent assay (MAb-ELISA) in the diagnosis of previous dengue infection using serum samples from the cohort study in Ratchaburi Province, Thailand.

methodsThe MAb-ELISA was compared to 70% plaque reduction neutralization test (PRNT70) in 453 serum samples from children aged 3-11 years in Ratchaburi Province, Thailand.

resultsThe sensitivity and specificity of MAb-ELISA at the positive to negative (P/N) ratio cut-off level of > 3 were both 0.91 in the diagnosis of previous dengue infection, compared to PRNT70. The false positivity was mainly in Japanese encephalitis (JE) seropositive subjects.

conclusionsThis research provides evidence that MAb-ELISA is useful for dengue seroprevalence study and dengue pre-vaccination screening. JE seropositivity was the major cause of false positive result in the study population.

Indexed as

Antibodies, MonoclonalAntibodies, ViralChildChild, PreschoolCohort StudiesDengueDengue VirusEnzyme-Linked Immunosorbent AssayHumansImmunoglobulin MMicrobiological TechniquesNeutralization TestsSensitivity and SpecificitySeroepidemiologic StudiesThailandAntibodies, MonoclonalAntibodies, ViralImmunoglobulin MDengueEnzyme-linked immunosorbent assayMonoclonal antibodyPlaque reduction neutralization test

Identifiers

PMID31665014
PMCPMC6820907
OpenAlexW2982687014

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.